Humanigen Inc (HGENQ)

[cowtown jay]

How ridiculous and uninformed it is to think that posting about other companies, whose platforms and drugs will benefit tremendously from lenz, have no bearing on this company. It's understandable that people may think that posting about other companies on this board doesn't belong here. But that only reflects a lack of appreciation of lenzilumab's capability. IN MY OPINION.

Tell that to Gilead, who tried to enhance azacitidine by acquiring '47 Inc.' for $4.9B, for their magrolimab MAB.

"Gilead to Acquire Forty Seven for $4.9 Billion"

https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion

"Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS"

https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds

And remember what Humanigen reported from the PREACH-M study of using lenz for CMML, versus Gilead's use of magrolimab.

"PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia"

https://www.news-medical.net/news/20230609/PREACH-M-trial-Lenzilumab-may-improve-treatment-response-in-chronic-myelomonocytic-leukemia.aspx

But you can certainly count me in on wanting to see, not just an update, but regulatory recognition and approval of lenz. The issue isn't that management owes us an update, it's that regulators, somewhere in the world, owe Humanigen authorization and approval of lenz.